CLDX FY 2022 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-49.3% YoY

Gross Profit

-$80M-3389.9% margin

Operating Income

-$115M-4889.0% margin

Net Income

-$112M-4765.6% margin

EPS (Diluted)

$-2.40

Cash Flow

Operating Cash Flow

-$104M

Free Cash Flow

-$106M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$353M

Total Liabilities

$27M

Stockholders' Equity

$326M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$5M	-49.3%
Gross Profit	-$80M	-$49M	-64.2%
Operating Income	-$115M	-$71M	-61.7%
Net Income	-$112M	-$71M	-59.3%